Cover Image
市場調查報告書

Ibodutant (大腸躁鬱症) - 2023年為止的預測與市場分析

Ibodutant (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 325979
出版日期 內容資訊 英文 56 Pages
訂單完成後即時交付
價格
Back to Top
Ibodutant (大腸躁鬱症) - 2023年為止的預測與市場分析 Ibodutant (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023
出版日期: 2014年12月31日 內容資訊: 英文 56 Pages
簡介

本報告提供大腸躁鬱症 (IBS) 治療藥物──Ibodutant之相關調查,提供您疾病概要與免疫學,疾病管理,競爭情形,未滿足需求機會,開發平台評估,主要企業的資訊,今後的市場預測等資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因與病理學
    • 病因
    • 病理學
  • 分類
  • 症狀
  • 預後
  • 生活品質 (QOL)

第4章 疾病的管理

  • 疾病和治療概要
    • 診斷
    • 治療指南主要的處方藥
    • 臨床診療

第5章 競爭評估

  • 概要

第6章 未滿足需求和機會

  • 概要
  • 更有效的藥物療法
    • 未滿足需求
    • 差距分析
    • 機會
  • IBS D類型的治療方法
    • 未滿足需求
    • 差距分析
    • 機會
  • IBS M類型的治療方法
    • 未滿足需求
    • 差距分析
    • 機會
  • 解決腹痛和飽脹感症狀的治療方法
    • 未滿足需求
    • 差距分析
    • 機會
  • 提高IBS的診斷率
    • 未滿足需求
    • 差距分析
    • 機會

第7章 開發平台評估

  • 概要
  • 臨床開發的潛力治療藥物

第8章 Ibodutant (MEN-15596)

  • 概要
  • 有效性
  • 安全性
  • 給藥與處方
  • 潛在的臨床性·商業性地位
  • SWOT分析
  • 預測

第9章 附錄

目錄
Product Code: GDHC522DFR

Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients' quality of life (QOL). In terms of volume, the IBS market is a large, albeit naive, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.

Ibodutant is being developed by Menarini for the treatment of women with IBS-D. The Phase III program for ibodutant was initiated in Q1 2014 with two Phase III clinical trials, a 12-week study and a 52-week study, both of which were designed to evaluate the efficacy and safety of this product (Menarini, NCT02107196; Menarini, NCT02120027).

Scope

  • Overview of IBS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Ibodutant including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Ibodutant for the top 7 countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, UK and Japan.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return.
  • Stay ahead of the competition by understanding the changing competitive landscape for IBS.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
  • Make more informed business decisions from insightful and in-depth analysis of Ibodutant performance.
  • Obtain sales forecast for Ibodutant from 2013-2023 in top 7 countries (the US, France, Germany, Italy, Spain, UK and Japan).

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification
  • 3.3. Symptoms
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. More Effective Pharmacotherapies
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Therapies for the IBS-D Subtype
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Therapies for the IBS-M Subtype
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Therapies to Address Abdominal Pain and Bloating Symptoms
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Improved Diagnosis Rate for IBS
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development

8. Ibodutant (MEN-15596)

  • 8.1. Overview
  • 8.2. Efficacy
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical and Commercial Positioning

8.6. SWOT Analysis

  • 8.7. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed IBS Patients
    • 9.4.2. General Pricing Assumptions
    • 9.4.3. Generic Erosion
    • 9.4.4. Pricing of Pipeline Agents
  • 9.5. Primary Research - KOLs Interviewed for This Report
  • 9.6. Primary Research - Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Analyst
    • 9.7.2. Therapy Area Director
    • 9.7.3. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Common Symptoms of IBS
  • Table 2: Summary of the Various Diagnostic Criteria Used for the Diagnosis of IBS
  • Table 3: Treatment Guidelines for IBS
  • Table 4: Leading Prescribed Drugs for IBS by Predominant Symptoms in the 7MM, 2014†
  • Table 5: Leading Branded Treatments for IBS, 2014
  • Table 6: Unmet Needs and Opportunities in IBS
  • Table 7: Drugs in Late-Stage Clinical Development for IBS, 2014
  • Table 8: Product Profile - Ibodutant
  • Table 9: Ibodutant SWOT Analysis, 2014
  • Table 10: Global IBS Sales Forecasts ($m) for Ibodutant, 2013-2023
  • Table 11: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: Summary of Pharmacotherapies Used to Treat IBS
  • Figure 2: IBS - Phase IIb-III Pipeline, October 2014
  • Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in IBS, 2013-2023
  • Figure 4: Clinical and Commercial Positioning of Ibodutant
Back to Top